Gültekin Bülent Kadri, Kesebir Sermin, Kabak Sevgi Gül, Ergün Ferzan Fikret, Tatlidil Yaylaci Elif
Clinic of Psychiatry, Erenköy Psychiatric Training and Research Hospital, İstanbul, Turkey.
Noro Psikiyatr Ars. 2014 Sep;51(3):229-232. doi: 10.4274/npa.y6827. Epub 2014 Sep 1.
Purinergic system dysfunction has been shown both in patients with bipolar disorder (BD) and those with schizophrenia. The aim of this study was to evaluate whether uric acid levels in male BD patients with manic episode and schizophrenia patients with psychotic relapse differ from healthy male subjects. Secondly to assess whether uric acid levels in both patient groups correlate with episode severity and if a decrease in uric acid levels correlate with clinical improvement.
A total of 55 BD patients with manic episode and 59 schizophrenic patients with psychotic relapse were evaluated at baseline and at weeks 1, 2, 3 using the Young Mania Rating Scale (YMRS) and the Positive and Negative Syndrome Scale (PANSS), and their plasma uric acid levels were measured. 60 age-matched healthy males without history of any previous or current psychiatric diagnosis and treatment constituted the control group. In order to determine plasma uric acid levels, blood samples were centrifuged at 3000 × g for 15 minutes, stored at -80°C and measured in milligrams per deciliter.
Uric acid levels in both patient groups with manic episode and psychotic relapse were found higher than in healthy controls (f=6.122, p=.027). The difference between repeated measurements of uric acid levels in BD patient group was found to be between baseline and first week measurements (after Bonferroni correction) (p<.001). No correlation was found between YMRS and PANSS scores and uric acid levels at 4 assessment times.
Uric acid levels in male BD and schizophrenia patients with manic episode and psychotic relapse were similar with each other, and higher than in healthy males. No correlation was found between uric acid levels and episode severity in both groups. However, for patients with BD, a decrease in uric acid levels between baseline and first week seems to be correlated with clinical improvement.
双相情感障碍（BD）患者和精神分裂症患者均已出现嘌呤能系统功能障碍。本研究的目的是评估伴有躁狂发作的男性BD患者和伴有精神病性复发的精神分裂症患者的尿酸水平是否与健康男性受试者不同。其次，评估两组患者的尿酸水平是否与发作严重程度相关，以及尿酸水平的降低是否与临床改善相关。
共有55例伴有躁狂发作的BD患者和59例伴有精神病性复发的精神分裂症患者在基线时以及第1、2、3周使用青年躁狂评定量表（YMRS）和阳性与阴性症状量表（PANSS）进行评估，并测量其血浆尿酸水平。60名年龄匹配、无任何既往或当前精神科诊断和治疗史的健康男性构成对照组。为了测定血浆尿酸水平，将血样以3000×g离心15分钟，储存在-80°C，以毫克每分升为单位进行测量。
发现伴有躁狂发作和精神病性复发的两组患者的尿酸水平均高于健康对照组（F = 6.122，P = 0.027）。BD患者组尿酸水平重复测量之间的差异发现在基线和第一周测量之间（经Bonferroni校正后）（P < 0.001）。在4个评估时间点，YMRS和PANSS评分与尿酸水平之间均未发现相关性。
伴有躁狂发作和精神病性复发的男性BD和精神分裂症患者的尿酸水平彼此相似，且高于健康男性。两组患者的尿酸水平与发作严重程度均未发现相关性。然而，对于BD患者，基线和第一周之间尿酸水平的降低似乎与临床改善相关。
